IDEXX Laboratories Inc (IDXX) stock
IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 17/3038% above fair value
$698.47+8.23 (+1.19%)
Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –
IDEXX Laboratories r&d expenses
Research and development expenses are spending on new products and technology.
IDEXX Laboratories's R&D Expenses for the twelve months ending Jun 30, 2026 was $261.47M, up 12.4% year over year. For fiscal 2025 it was $251.21M, up 14.3% from the year before. Over ten years it grew 9.7% a year on average. The highest annual figure on record is $254.82M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $251.21M | +14.3% |
| FY2024 | Dec 31, 2024 | $219.79M | +15.1% |
| FY2023 | Dec 31, 2023 | $190.95M | -25.1% |
| FY2022 | Dec 31, 2022 | $254.82M | +58.3% |
| FY2021 | Dec 31, 2021 | $161.01M | +14.0% |
| FY2020 | Dec 31, 2020 | $141.25M | +6.0% |
| FY2019 | Dec 31, 2019 | $133.19M | +13.0% |
| FY2018 | Dec 31, 2018 | $117.86M | +8.0% |
| FY2017 | Dec 31, 2017 | $109.18M | +8.0% |
| FY2016 | Dec 31, 2016 | $101.12M | +1.4% |
| FY2015 | Dec 31, 2015 | $99.68M | +1.4% |
| FY2014 | Dec 31, 2014 | $98.26M | +11.7% |
| FY2013 | Dec 31, 2013 | $88.00M | +7.3% |
| FY2012 | Dec 31, 2012 | $82.01M | +7.9% |
| FY2011 | Dec 31, 2011 | $76.04M | +10.9% |
| FY2010 | Dec 31, 2010 | $68.60M | +5.3% |
| FY2009 | Dec 31, 2009 | $65.12M | -7.9% |
| FY2008 | Dec 31, 2008 | $70.67M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $65.43M | +5.7% |
| Q1 FY2026 | Mar 31, 2026 | $65.79M | +11.4% |
| Q4 FY2025 | Dec 31, 2025 | $66.83M | +15.8% |
| Q3 FY2025 | Sep 30, 2025 | $63.42M | +17.5% |
| Q2 FY2025 | Jun 30, 2025 | $61.90M | +11.6% |
| Q1 FY2025 | Mar 31, 2025 | $59.06M | +12.2% |
| Q4 FY2024 | Dec 31, 2024 | $57.73M | +11.4% |
| Q3 FY2024 | Sep 30, 2024 | $53.98M | +12.5% |
| Q2 FY2024 | Jun 30, 2024 | $55.45M | +19.2% |
| Q1 FY2024 | Mar 31, 2024 | $52.64M | +17.8% |
| Q4 FY2023 | Dec 31, 2023 | $51.81M | +19.3% |
| Q3 FY2023 | Sep 30, 2023 | $47.97M | -0.1% |
| Q2 FY2023 | Jun 30, 2023 | $46.51M | -62.3% |
| Q1 FY2023 | Mar 31, 2023 | $44.67M | +11.2% |
| Q4 FY2022 | Dec 31, 2022 | $43.42M | -4.2% |
| Q3 FY2022 | Sep 30, 2022 | $48.01M | +18.8% |
| Q2 FY2022 | Jun 30, 2022 | $123.22M | +226.9% |
| Q1 FY2022 | Mar 31, 2022 | $40.17M | +6.9% |
| Q4 FY2021 | Dec 31, 2021 | $45.31M | +16.8% |
| Q3 FY2021 | Sep 30, 2021 | $40.43M | +7.8% |
| Q2 FY2021 | Jun 30, 2021 | $37.70M | +19.1% |
| Q1 FY2021 | Mar 31, 2021 | $37.58M | +12.8% |
| Q4 FY2020 | Dec 31, 2020 | $38.78M | +10.3% |
| Q3 FY2020 | Sep 30, 2020 | $37.52M | +9.5% |
| Q2 FY2020 | Jun 30, 2020 | $31.65M | -1.9% |
| Q1 FY2020 | Mar 31, 2020 | $33.31M | +5.7% |
| Q4 FY2019 | Dec 31, 2019 | $35.16M | +16.7% |
| Q3 FY2019 | Sep 30, 2019 | $34.26M | +17.4% |
| Q2 FY2019 | Jun 30, 2019 | $32.26M | +9.3% |
| Q1 FY2019 | Mar 31, 2019 | $31.51M | +8.6% |
| Q4 FY2018 | Dec 31, 2018 | $30.14M | +4.6% |
| Q3 FY2018 | Sep 30, 2018 | $29.19M | +5.8% |
| Q2 FY2018 | Jun 30, 2018 | $29.51M | +9.3% |
| Q1 FY2018 | Mar 31, 2018 | $29.02M | +12.5% |
| Q4 FY2017 | Dec 31, 2017 | $28.81M | +13.3% |
| Q3 FY2017 | Sep 30, 2017 | $27.59M | +7.5% |
| Q2 FY2017 | Jun 30, 2017 | $27.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $25.79M | – |
| Q4 FY2016 | Dec 31, 2016 | $25.42M | – |
| Q3 FY2016 | Sep 30, 2016 | $25.67M | – |
See a number that looks wrong?